Product Program year 2024 Source: CMS Open Payments

Methylphenidate Hydrochloride

Drug Neurology - ADHD medication

NDC 13811-709-10

Open in the dashboard

General payments

$17,947

964 payments

Research payments

$0

0 payments

Through program year 2024, $17,947 in general payments and $0 in research payments were reported against Methylphenidate Hydrochloride (Neurology - ADHD medication).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2024 General $1,561 84
2023 General $16,387 880

Breakdown

Who paid General payments · program years 2023–2024
  1. Avion Pharmaceuticals $17,490 935 payments
  2. Vertical Pharmaceuticals, LLC $457 29 payments
Top recipients General payments · program year 2024
  1. Robert Chudnow Neurology with Special Qualifications in Child Neurology · Plano, TX $41 3% · 2 payments
  2. Jorge Maldonado Psychiatry · San Antonio, TX $33 2% · 1 payment
  3. Shelly Reardon Neurology with Special Qualifications in Child Neurology · Austin, TX $33 2% · 1 payment
  4. Daniel Gustkey Epilepsy · Austin, TX $33 2% · 1 payment
  5. Theresa Sakyiama Child & Adolescent Psychiatry · Wheaton, IL $24 2% · 1 payment

The top 5 of 83 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Pediatrics $345 22% · 21 practitioners
  2. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $281 18% · 14 practitioners
  3. Psychiatry Psychiatry & Neurology $246 16% · 13 practitioners
  4. Neurology with Special Qualifications in Child Neurology Psychiatry & Neurology $170 11% · 7 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $153 10% · 9 practitioners

The top 5 of 15 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Texas $498 32% · 23 recipients
  2. Ohio $381 24% · 23 recipients
  3. California $139 9% · 6 recipients
  4. Rhode Island $138 9% · 7 recipients
  5. Indiana $131 8% · 9 recipients

The top 5 of 10 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

202

Prescriptions dispensed, refills included

Drug cost

$56,932

Paid at the pharmacy, in all

Prescribers

17

With 11 or more claims of it

Medicare Part D drugs matched to Methylphenidate Hydrochloride, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Methylphenidate Similar name 17 202 $56,932

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 17 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Donna Fargason Psychiatry & Neurology LA 19 $7,300 None on record
Stephan Becker Psychiatry AK 13 $3,011 None on record
Judith Badner Psychiatry IL 12 $4,560 No profile
Kombiz Klein Internal Medicine NC 12 $4,083 None on record
Naomi Bikle Psychiatry HI 12 $2,966 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 17 in the dashboard with a free account
964 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record